Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRETON vs METRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Type 2 diabetes mellitus,Polycystic ovary syndrome (off-label)
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Adults: 20 mg orally once daily.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Not extensively metabolized; primarily excreted unchanged in urine.
Metformin is excreted unchanged in urine; does not undergo hepatic metabolism or cytochrome P450 metabolism.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
75-85% bound to albumin and alpha-1-acid glycoprotein
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
0.5-1.0 L/kg; indicates moderate tissue distribution
Vd: 1.5-2.5 L/kg (mean 2.0 L/kg). Extensive tissue distribution; crosses blood-brain barrier and placenta.
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
Oral: 60-75% (due to first-pass metabolism); intramuscular: 90-100%; topical: 10-20% (formulation-dependent).
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
e GFR ≥30 m L/min: no adjustment; e GFR <30 m L/min: 10 mg once daily.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Weight ≥30 kg: 20 mg once daily; weight <30 kg: 10 mg once daily.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
≥65 years: initial dose 10 mg once daily, titrate as tolerated.
None
Lactic acidosis: Metformin use has been associated with lactic acidosis, a rare but serious metabolic complication. Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years, and hepatic disease.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Lactic acidosis risk, impaired renal function (monitor e GFR), vitamin B12 deficiency, acute metabolic acidosis, perioperative use, and concurrent iodinated contrast agents.
Hypersensitivity to any component of the formulation
Severe renal impairment (e GFR <30 m L/min/1.73 m²), acute metabolic acidosis, severe hepatic disease, and hypersensitivity to metformin.
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Avoid high-sodium foods as they may counteract the antihypertensive effect. Consumption of potassium-rich foods (e.g., bananas, oranges) is not restricted unless hypokalemia develops, but monitor potassium levels. Grapefruit juice may increase metolazone absorption; avoid concurrent use. Limit alcohol intake as it may enhance hypotensive effects.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimester. Second and third trimester exposure may cause low birth weight and transient neonatal metabolic disturbances. Use effective contraception during treatment.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
METRA is excreted into human breast milk with an M/P ratio of approximately 0.8 to 1.2. Due to potential adverse effects in nursing infants, such as immunosuppression and growth delay, breastfeeding is not recommended during therapy and for 12 months after last dose.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
No dosing adjustments are recommended because METRA is contraindicated in pregnancy. In the rare event of inadvertent use during pregnancy, immediate discontinuation is required. Pharmacokinetic changes in pregnancy (increased clearance, reduced protein binding) do not apply as therapy must be ceased.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
METRA is a brand name for metolazone, a thiazide-like diuretic. Use with caution in severe renal impairment (e GFR <20 m L/min) as effectiveness diminishes. Monitor for hypokalemia, especially when used with loop diuretics. Do not use in hepatic coma or pre-coma.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness due to blood pressure changes; rise slowly from sitting or lying positions.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or extreme thirst.,Do not consume alcohol or take other blood pressure medications without consulting your doctor.
No interactions on record
"Concurrent use of Phenmetrazine, a sympathomimetic amine with central nervous system stimulant activity, and Isoxsuprine, a beta-adrenergic receptor agonist with peripheral vasodilatory effects, may result in additive stimulation of the cardiovascular system. This can lead to synergistic increases in heart rate, myocardial contractility, and blood pressure, potentially precipitating hypertensive crisis, tachycardia, arrhythmias, or myocardial ischemia. Clinically, this interaction poses significant risks for patients with underlying cardiovascular disease, and careful monitoring is essential if concomitant use is unavoidable."
"The combination of Phenmetrazine, a sympathomimetic appetite suppressant, with Oxymetazoline, a direct-acting alpha-adrenergic agonist, can lead to additive vasoconstriction and hypertensive effects. This interaction may precipitate a hypertensive crisis, especially in patients with underlying cardiovascular disease, and can result in adverse outcomes such as myocardial ischemia, stroke, or arrhythmias. Concurrent use should be avoided due to the potential for severe cardiovascular adverse events."
"Amphetamine and phenmetrazine are both central nervous system (CNS) stimulants that increase synaptic norepinephrine and dopamine by promoting release and blocking reuptake. Concurrent use synergistically amplifies adrenergic and dopaminergic signaling, leading to excessive CNS stimulation and cardiovascular strain. This can manifest as severe hypertension, tachyarrhythmia, hyperthermia, agitation, serotonin syndrome-like symptoms, and potentially life-threatening events such as stroke or myocardial infarction."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRETON vs METRA, answered by our medical review team.
METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. METRA is a Antibiotic (Nitroimidazole) that works by Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRETON and METRA depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. The standard adult dose of METRA is: Adults: 20 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRETON and METRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. METRA is classified as Category C. METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.